Oramed Pharmaceuticals stock (US68403P1003): Oral drug delivery innovator for US diabetes market

Oramed Pharmaceuticals advances oral insulin and GLP-1 therapies, targeting the massive US diabetes treatment market with needle-free alternatives amid growing demand for convenient delivery options.

Oramed Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on oral delivery of proteins and peptides, including insulin for diabetes management. The company recently highlighted progress in its pipeline, positioning it as a potential disruptor in the US diabetes sector where over 38 million Americans live with the condition.

Oramed's lead candidate, ORMD-0801 oral insulin, has shown promising results in late-stage trials, offering a non-invasive alternative to injections. This development is particularly relevant for US investors given the $50 billion-plus annual diabetes drug market dominated by injectables from players like Novo Nordisk and Eli Lilly. Oramed website as of 05/14/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Oramed Pharmaceuticals Inc.
• Sector/industry: Biopharmaceuticals / Oral drug delivery
• Headquarters/country: Israel
• Core markets: US, Europe (diabetes treatments)
• Key revenue drivers: Pipeline milestones, partnerships, royalties
• Home exchange/listing venue: Nasdaq (ORMP)
• Trading currency: USD

Oramed Pharmaceuticals: core business model

Oramed Pharmaceuticals develops proprietary technologies for oral administration of previously injectable drugs, primarily targeting metabolic diseases like diabetes. Its Protein Oral Delivery (POD) platform uses specialized capsules to protect macromolecules from stomach acid, enabling absorption in the intestines. This addresses a key patient pain point in adherence due to injection fatigue.

The company's business model centers on advancing its pipeline to regulatory approval, then partnering with big pharma for commercialization and royalties. Oramed holds over 20 patents protecting its technology globally, providing a moat against competitors. US listing on Nasdaq facilitates access to capital for trials relevant to American regulators.

Main revenue and product drivers for Oramed Pharmaceuticals

Pipeline progress drives value, with ORMD-0801 (oral insulin) in Phase 3 trials showing glycemic control comparable to injected insulin in prior studies published in 2023. ORMD-0701, an oral GLP-1 analog for obesity and diabetes, completed Phase 2 with positive weight loss data. These target the exploding US GLP-1 market, valued at $20 billion in 2025 per IQVIA reports.

Future revenues could stem from milestone payments, as seen in past deals, and eventual product sales or royalties. Diabetes exposure ties Oramed to US healthcare spending trends, where oral options could capture share from high-cost injectables amid payer pressure for affordability.

Industry trends and competitive position

The oral delivery space is heating up with advances in nanotechnology and formulation science, but Oramed's POD technology stands out for human data in insulin delivery. Competitors like Novo Nordisk explore similar tech, yet Oramed's focus on generics-compatible delivery offers cost advantages. US FDA's interest in patient-centric innovations supports Oramed's path.

Why Oramed Pharmaceuticals matters for US investors

Listed on Nasdaq, Oramed provides direct exposure to Israel's biotech ecosystem while serving the US diabetes epidemic affecting 14% of adults. Success in trials could yield partnerships with US giants, boosting royalties amid rising obesity rates driving GLP-1 demand.

Conclusion

Oramed Pharmaceuticals continues to advance its oral delivery platform, with key assets in late-stage development for diabetes and obesity treatments. While regulatory and trial risks remain, the company's technology addresses unmet needs in a high-growth US market. Investors track upcoming data readouts and partnership announcements for next steps.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.